A Profitable Rare-Disease Prize: Who Might Snap Up BioCryst?
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose by…



















